CCM
TCRR

Copernicus Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Copernicus Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,000
Closed -$492K – 21
2021
Q2 		$492K Buy
+30,000
New +$606K 7.76% 5

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Copernicus Capital Management's TCRR Position: Q3 2021 in Review

Copernicus Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 30,000 shares — an estimated $492K sold.

Copernicus Capital Management first reported a position in TCRR in Q2 2021 and held it in 1 quarter. The position peaked at $492K in Q2 2021. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Copernicus Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 30,000 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $492K.
  • Copernicus Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Copernicus Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $492K in Q2 2021.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.